Previous close | 4.92 |
Open | 5.70 |
Bid | 5.30 |
Ask | 5.45 |
Strike | 70.00 |
Expiry date | 2024-06-21 |
Day's range | 5.70 - 5.70 |
Contract range | N/A |
Volume | |
Open interest | 520 |
FOSTER CITY, Calif., March 28, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.
FOSTER CITY, Calif. & WALTHAM, Mass., March 28, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
In this article, we will be taking a look at the 20 biggest health care companies in Australia, 2024. If you do not want to learn about the global healthcare market, head straight to the 5 Biggest Health Care Companies in Australia, 2024. In 2024, Australia’s healthcare landscape will be dominated by a myriad of […]